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Aims: To review population surveys to assess (a) prevalence of the use of NRT for smoking reduction(SR) and temporary abstinence (TA) and (b) how far this is associated with attempts to stop
smoking, smoking cessation and reduction in cigarette consumption.
Methods: An electronic search was undertaken of EMBASE, MEDLINE, Web of Science and PsycINFO.
Articles were selected if they (1) assessed whether smokers had used or were currently using NRT
for SR and/or TA; (2) involved smokers who had not taken part in a harm reduction programme; and
(3) assessed prevalence and/or association of SR and/or TA with reductions in cigarette consumption
and/or attempts to stop smoking and/or with smoking cessation. Twelve studies met the inclusion
criteria and results were extracted independently by two researchers.
Results: Data were available from five countries (US, UK, Canada, Switzerland and Australia). Between
1% and 23% of smokers reported having ever used NRT for smoking reduction and between 2% and
14% during periods of temporary abstinence. Use of NRT for SR and/or TA was associated with little or
no reduction in cigarette consumption. There was some evidence that it was positively associated with
attempts to stop smoking and smoking cessation.
Conclusion: In smoking populations use of NRT to aid SR and in situations where smoking is not
permitted appears to be having little effect on achieving a reduction in cigarette consumption but does
not undermine cessation and may promote it.
Keywords: harm reduction, smoking reduction, temporary abstinence, NRT
Introduction
Tobacco harm reduction involves attempting to reduce the
physical and/or psychological harm from smoking with-
out complete cessation of tobacco. One type of harm re-
duction is the use of nicotine replacement therapy (NRT)
for smoking reduction. Another involves use of NRT in
situations when smoking is not permitted, i.e., during pe-
riods of temporary abstinence. Data from clinical trials
indicate that use of NRT for smoking reduction may re-
sult in significant reductions in cigarette consumption and
toxin intake (Asfar et al., 2011; Fagerstrom, 2005; Hughes,
2000; Hughes &Carpenter, 2006;Moore et al., 2009; Stead
Address for correspondence: Emma Beard, PhD, Cancer Research UK Health Behaviour Research Centre, University College London, WC1E 6BP.
E-mail: e.beard@ucl.ac.uk. Tel: 020 31083179.
& Lancaster, 2007; Tonnesen, 2002; Wang et al., 2008;
Zellweger, 2001). However, a potential unwanted conse-
quence of such an activity is that it may undermine moti-
vation to stop smoking altogether. Data from clinical trials
suggests that, on the contrary, use of NRT for smoking re-
duction could increase the rate at which smokers try and
succeed in stopping (Asfar et al., 2011; Fagerstrom, 2005;
Hughes, 2000; Hughes & Carpenter, 2006; Moore et al.,
2009; Stead&Lancaster, 2007;Tonnesen, 2002;Wanget al.,
2008; Zellweger, 2001).
However, there are several reasons why these data may
not mean that people who reduce smoking in the general
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population aremore likely to reduce or stop smoking than
those who do not. First, in trials NRT was provided free of
charge and this may have helped to ensure that usage was
at the level required to achieve a clinically significant effect.
Secondly, the regular follow-up and behavioural support
provided in the clinical trialsmay have helped participants
to gain benefit from NRT which may not occur without
such support. Thirdly, the volunteers for the trials may
have been more highly motivated to reduce their smoking
than those using NRT in the population of smokers as
a whole. Fourthly, in the general population of smokers
there are significant numbers of people withmental health
problems and these are usually excluded from clinical tri-
als; such smokers may experience particular difficulties in
achieving smoking reduction.
Consequently, the current review aimed to assess how
far the use of NRT for smoking reduction and/or tem-
porary abstinence is associated with (i) attempts to stop
smoking and smoking cessation, and (ii) reduction in
cigarette consumption, in the population. The current re-
view presents data comparing those using NRT for smok-
ing reduction and/or temporary abstinence to (i) other
smokers generally, (ii) smokers using NRT for smoking
cessation, and (iii) smokers attempting to cut down or to
temporarily abstain without NRT. The third comparison
provides the most valid data regarding the ‘effectiveness’
of NRT use for harm reduction purposes at a population
level; with any difference being attributed to the use of
NRT. In comparison, any difference amongst those using
NRT for smoking reduction and/or temporary abstinence
and other smokers, could be due to their use of NRT or
a consequence of their attempts to reduce their cigarette
intake.
A secondary aim was to determine how many smok-
ers are using NRT for smoking reduction and/or tem-
porary abstinence. This is important from a policy per-
spective, providing an indication as to the likely uptake of
population-based reduction programmes. The most use-
ful data presented are those from random/quasi random
population surveys of smokers, as these provide a reli-
able estimate of the number of smokers using NRT for
smoking reduction and/or temporary abstinence in the
population. It is of additional interest to ascertain the
socio-demographic and smoking characteristics of those
using NRT for harm reduction purposes for two reasons:
(1) to inform population-based interventions as to those
who may be the most interested in a harm reduction ap-
proach and (2) to determine whether harm reduction ap-
proaches are targeting a set of smokers previously ignored
by conventional tobacco control approaches.
Methods
Edibility criteria
Studies were initially selected on the basis of whether the
target population were smokers and whether the studies
had been published. Further selection was then based on
whether the studies (1) involved the assessment of smok-
ers who had used or were currently using NRT for smok-
ing reduction and/or temporary abstinence; (2) involved
smokers who had not taken part in a harm reduction
programme; and (3) assessed prevalence and/or associa-
tion with cigarette consumption and/or association with
attempts to quit smoking and/or smoking cessation.
Information sources
The electronic databases EMBASE, MEDLINE, Web of
Science and PsycINFO, were searched up to March
2011. The search combined four parameters: smoking
(smok*, cigarette, tobacco), NRT (nicotine, NRT), smok-
ing reduction and/or temporary abstinence (smoking
reduction, cut down, cutting down, reduce, schedule,
gradual, controlled smoking, temporary abstinence,
smoke-free, smoking restriction, harm reduction, risk re-
duction), and smoking cessation (quit, cessation, inten-
tion, motivation, cease, desire, stop). References of se-
lected studies were screened and independent journal
searches conducted (TobaccoControl;Nicotine&Tobacco
Research; Addiction) using the journals website search
facilities.
Study selection and data collection process
The title and abstract of studies found from the above in-
formation sources were assessed for initial inclusion cri-
teria. The full articles of eligible studies which met these
criteria were then screened to ascertain whether they met
the specific inclusion criteria. Data were abstracted inde-
pendently by two researchers using a structured data ab-
straction form, which included socio-demographic and
smoking characteristics, the country in which the study
was conducted, method of recruitment, prevalence data
and differences among groups in cigarette consumption,
attempts to quit smoking and smoking cessation. Dis-
agreements were discussed and resolved, with 90% agree-
ment attained.
Quality assessment and risk of bias
Study quality was assessed using criteria adapted
fromtheNewcastle-Ottawa scale (www.ohri.ca/programs/
clinical_epidemiology/nosgen.pdf), recommended by
Cochrane reviewers (Higgins & Green, 2008): (1) Rep-
resentativeness of the sample (do recruitment methods
result in a sample of smokers representative of the gen-
eral population?), (2) validity of measurements (is the use
of NRT for smoking reduction assessed retrospectively or
currently?), (3) adequate sample size (is the study suffi-
ciently powered?), and (4) study design (is the study cross-
sectional or prospective?). Two separate quality measures
were produced for those looking at prevalence and ef-
fectiveness of NRT for harm reduction. Quality was rated
good,moderate or poor. Studies assessing prevalence were
classed as good quality if they: (1) recruited representative
samples; (2)with an adequate sample size and; (3) assessed
current use of NRT. They were classed as moderate if they
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satisfied two of these criteria, and poor if they satisfied less
than one. Those assessing the effectiveness were classed as
good quality if they satisfied at least three of the following:
(1) adequate sample size, (2) representative sample, (3)
assessment of current NRT use, and (4) used a prospec-
tive design. They were classed as moderate quality if they
satisfied two, and poor quality if they satisfied less than
one. Potential risks of bias from the included studies were
also considered.
Outcome measures
For studies assessing the number of smokers using NRT
for harm reduction purposes, the primary outcomes were
current prevalence, cumulative prevalence, and initial rea-
sons for purchasing NRT. For those measuring cessa-
tion, the primary outcomes for the review were quit at-
tempts and smoking status. Finally, for studies measuring
consumption, the primary outcomes were differences in
cigarette consumption, changes in nicotine intake (mea-
sured by salivary cotinine), average percentage reduction
in cigarette consumption from baseline, or the number of
those attaining a reduction in cigarette consumption of
50% or more.
Synthesis of results
Due to the diversity of methods used across studies,
a meta-analysis could not be conducted; therefore a
narrative synthesis of the findings was undertaken. This
involved assessing the average and distribution of preva-
lence estimates and the direction and consistency of as-
sociations reported. PRISMA guidelines were followed
throughout (Moher et al., 2009). Studies assessing preva-
lence using population-based surveys were reported sepa-
rately from those which surveyed NRT users only or those
studies with biased recruitment methods. Studies assess-
ing cigarette consumption, attempts to quit smoking, and
smoking cessation, were split according to study design:
cross-sectional, prospective and mixed (cross-sectional
and prospective).
Results
Study selection
Fifteen studies were identified; three studies used
data from the Smoking Toolkit Study (www.
smokinginengland.info) (Beard et al., 2011a; Beard
et al., 2011b; Beard et al., in press) and two from
the International Tobacco Control Four Country Study
(www.itcproject.org/) (Hammond et al., 2008; Shahab
et al., 2009); these were combined [reported as STS and
ITC, respectively], leaving 12 studies overall (see Figure 1).
The paper by Hughes and colleagues (2004) included two
studies which are denoted throughout as (2004a) and
(2004b), respectively. Eleven of the studies assessed the
proportion of smokers using NRT for smoking reduc-
tion and/or temporary abstinence, six assessed the issue
of cigarette consumption, and three assessed attempts to
quit smoking and/or smoking cessation.
Study characteristics
All 12 studies were conducted in one or more of the fol-
lowing countries: US, UK, Canada, Switzerland and Aus-
tralia (see Table 1). In six of the studies, recruitment in-
volved telephone surveys using random digit dialling with
a panel of respondents. Three studies used advertisements
in pharmacies or newspapers and one study used ran-
dom location sampling (STS). Hughes et al. (2005) also
recruited smokers who had phoned a help line for the in-
halator or who had recently collected a prescription for
the product. A further three studies recruited participants
who had taken part in a smoking cessation programme
and had failed to quit smoking (Etter et al., 2003; Hughes
et al., 2004; Shiffman et al., 2003).
Of the 11 studies assessing the number of smok-
ers using NRT for smoking reduction and/or tempo-
rary abstinence, seven surveyed current and ex-smokers
(Al-Delaimy et al., 2005; Bansal et al., 2004; Etter et al.,
2003; ITC; Levy et al., 2007; Thorndike, 2002; STS),
while four surveyed gum users (Hughes, 2004ab; Shiff-
man et al., 2003) or inhalator users only (Hughes et al.,
2005). Current NRT use for smoking reduction and/or
temporary abstinence was measured in three of the stud-
ies (Hughes et al., 2004 a; Shiffman et al.,, 2003; STS),
lifetime use of NRT or cumulative prevalence in five
of the studies (Al-Delaimy et al., 2005; Bansal et al.,
2004; Etter et al., 2003; Levy et al., 2007; Thorndike
et al., 2002), and use of NRT in the past year in
one study (ITC). Three studies assessed whether smok-
ers had initially purchased NRT for smoking reduc-
tion and/or temporary abstinence (Hughes et al., 2004ab;
Hughes et al., 2005). Of those assessing cigarette con-
sumption and/or quit attempts, three were cross-sectional
(Etter et al., 2003; ITC; Hughes et al., 2004b), one prospec-
tive (Hughes et al., 2004) and two used a mixed de-
sign (Levy et al., 2007; STS). Follow-ups ranged from six
months to five years (Hughes et al., 2004; Levy et al., 2007;
STS). Two of the studies compared smokers who were
using NRT for smoking reduction and/or temporary ab-
stinence to those who were cutting down or temporarily
abstaining without NRT (Hughes et al., 2004; STS); two
compared smokers who had used NRT for smoking re-
duction and/or temporary abstinence to other smokers
generally (Etter et al., 2003; Levy et al., 2007); and one
compared those who had used NRT for smoking reduc-
tion and/or temporary abstinence to those who had used
NRT for smoking cessation purposes (ITC). A further
study compared smokers’ current cigarette consumption
with their retrospectively reported cigarette intake prior
to NRT use (Hughes et al., 2004a).
The use of NRT for smoking reduction was assessed
by asking participants if they had ever used NRT to reduce
the amount they smoked. The use of NRT for temporary
abstinence was assessed by asking participants if they had
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Table 1
Characteristics of the selected studies for inclusion in the systematic review
Study Aims Recruitment/Study year Participants Outcomes
Beard et al.
2011a
Prevalence of NRT use for harm reduction;
Compared those who were using NRT to
cut down or for temporary abstinence to
those who were cutting down or
temporarily abstaining without NRT.
Random location sampling
(2007 to 2009)
11, 414 current smokers. Mean age 41 (SD 16) and 49% male. Thirty-six
were in manual occupational groups or unemployed. Average
cigarette consumption 13 (SD 8.4).
Prevalence of NRT use for harm reduction
Change in prevalence over time
Cigarette consumption
Quit attempt in the past year
Beard et al.
2011b
Prevalence of NRT use for harm reduction;
Compared those who were using NRT to
cut down or for temporary abstinence to
those who were cutting down or
temporarily abstaining without NRT.
Random location sampling
(2007 to 2010)
52 current smokers. Mean age 45.6 (SD 13.00) and 39.5% male.
Thirty-five were in manual occupational groups or unemployed.
Average cigarette consumption 15.7 (SD 6.93).
Change in cigarette consumption among
those starting and stopping the use of
NRT
Change in salivary cotinine levels among
those starting and stopping the use of
NRT
Beard et al. in
press
Prevalence of NRT use for harm reduction;
Compared those who were using NRT to
cut down or for temporary abstinence to
those who were cutting down or
temporarily abstaining without NRT.
Random location sampling
(2007 to 2010 with
follow-up 2007 to 2010)
3,149 current smokers. Mean age 46.1 (SD 15.42) and 46% male.
Thirty-four were in manual occupational groups or unemployed.
Average cigarette consumption 14.1 (SD 8.61).
Prevalence of NRT use for harm reduction
Quit attempt between baseline and
follow-up
Smoking status at follow-up
Change in cigarette consumption among
those starting and stopping the use of
NRT
Hammond et al.
2008 US, UK,
Canada and
Australia
Prevalence of NRT use for harm reduction in
past year; Compared those who had used
NRT for smoking reduction, temporary
abstinence and for abrupt cessation
purposes in the past year
Probability sample with
random digit dialling.
(2005)
Canada 1,660 current smokers, 57.2% male, 67.1% aged 40+. 30.4%
of high income and 15.2% with higher education. Smoked an average
17.1 (SD 9.4) cigarettes per day.
UK 1,617 current smokers, 56.5% male, 69.6% aged 40+. 27.1% of
high income and 13.6% with higher education. Smoked an average
17.2 (SD 9.2) cigarettes per day.
US 1,644 current smokers, 59.0% male, 71.1% aged 40+. 22.6% of
high income and 18% with higher education. Smoked an average
18.7 (SD 11.5) cigarettes per day.
Australia 1,591 current smokers, 55.3% male, 59.7% aged 40+. 31.9%
of high income and 14.5% with higher education. Smoked an average
18 (SD 10.1) cigarettes per day.
Prevalence of NRT use for harm reduction
Intention to quit
Quit attempt in the past 12 months
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Table 1
Continued.
Study Aims Recruitment/Study year Participants Outcomes
Shahab et al.
2009
US, UK, Canada
and Australia
Prevalence of NRT use for harm reduction Probability sample with
random digit dialling
(2004 and 2007 surveys)
Canada/US/Australia: 10,845 current and ex-smokers. 43.5% male,
with a mean age of 45.6 (SD 16.5). 32.9% of low income and 15.4%
with high level of education. Average cigarette consumption per day
among current smokers (n = 10,331) 18.2 (SD 12.0)
UK: 3,554 current and ex-smokers. 43.9% male, with a mean age of
48.0 (SD 16.3). 34.2% of low income and 12.5% with high level of
education. Average cigarette consumption per day among current
smokers (n = 3,374) 17.1 (SD 10.2)
Prevalence of NRT use for harm reduction
Change in prevalence over time
Al-Delaimy
et al. 2005
US
Prevalence of NRT use for harm reduction Probability sample with
random digit dialling
(2002)
5,498 current smokers Prevalence of NRT use for harm reduction
Bansal et al.
2004
US
Prevalence of NRT use for harm reduction Probability sample with
random digit dialling.
(2001)
1,046 current smokers. Mean age of 41 years and 45.4% male. 20%
non-white, 50% reported more than 12 years in formal education,
25% smoked more than 25 cigarettes per day.
Prevalence of NRT use for harm reduction
Etter et al. 2003
Switzerland
Prevalence of NRT use for harm reduction;
Assessed the impact of messages that NRT
could be used for harm reduction purposes
on smokers’ motivation to quit
Smokers who had
participated in
Stop-tabac.ch were sent
emails asking if they
would like to participate.
(2002)
2,027 current and ex-smokers in total (299 control, 281 received a
temporary abstinence message and 230 received a reduction
message). Mean age of 37 and 41% male. Average cigarettes per day
20.
Prevalence of NRT use for harm reduction
Motivation to quit in response to
messages that NRT could be used for
harm reduction
Impact of messages on motivation to use
NRT
Hughes et al.
2004
US
Whether those who failed to quit following a
cessation programme managed to reduce
their intake with and without the use of
NRT
Smokers were initially
recruited from cardiology
clinics. (1987–1989 with
follow up 1988–1994)
1,722 smokers who had participated in a smoking cessation programme
and who were smoking daily three months prior to follow-up. Mean
age 58 (SD 7) and 55% male. 54% had more than a high school
education. Average cigarettes per day 32 (SD 13).
50% reduction in cigarette consumption
between baseline and follow-up
Hughes et al.
2004a
US
Reasons for initially using the nicotine gum
and currently using the gum.
Advertisements in
newspapers and
pharmacy. (1997)
266 nicotine gum users. Mean age of 46 (SD 13) and 38% male. Average
cigarette consumption per day of 21 (SD 14) and mean FTND of 5
(SD 2).
Prevalence of NRT use for harm reduction
Retrospective change in cigarette
consumption
Hughes et al.
2004b
US
Reasons for initially using the nicotine gum Advertisements placed in
newspapers. (2000)
100 nicotine gum users. Mean age 50 years (SD 10) and 41% male.
Average cigarette consumption of 30 (SD 15) and FTND of 6.7
(SD 1.8).
Prevalence of NRT use for harm reduction
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Table 1
Continued.
Study Aims Recruitment/Study year Participants Outcomes
Hughes et al.
2005
US
Reasons for using the nicotine inhalator Advertisements, pharmacy
attained prescription
records and those calling
a helpline about the
inhalator. (2000)
535 users of nicotine inhalators. Mean age 44 and 37% male. 68% had
a college education or more. Average cigarette consumption of 25
and FTND of 5.3.
Prevalence of NRT use for harm reduction
Stability of NRT use
Levy et al. 2007
US
Prevalence of NRT use for harm reduction;
Compared those who had ever used NRT to
cut down, to delay their smoking or to
delay and cut down, with those who had
not used NRT for such purposes
Probability sample with
random digit dialling.
(2001 to 2002 with
follow up 2003 to 2004)
3,084 current smokers, 41% over the age of 40.
48.1% male. 24.1% with BA/BSc or higher and 24.2% with an income of
$75,000+. Average cigarettes per day 31.15. 62.0% reported
smoking within 30 minutes of wakening.
Prevalence of NRT use for harm reduction
Cigarette consumption
Quit attempt in the past year
Motivation to quit
50% reduction from baseline to follow-up
Quit attempt between baseline and
follow-up
Smoking status at follow-up
Shiffman et al.
2003
US
Prevalence of NRT use for harm reduction;
Reasons for using NRT concurrently with
cigarettes following the failure of a
smoking cessation intervention
Those enrolled in a smoking
cessation intervention
and who had not quit
smoking and continued
to use NRT. (1996).
2,655 nicotine gum users. Mean age 42.2 (SD 12.8) and 55.8% male.
Average cigarette consumption 26.6 (11.9). Average of 13.6 (SD 2.1)
years in education.
Prevalence of NRT use for harm reduction
Extent of NRT use whilst concurrently
smoking.
Thorndike et al.
2002
US
Prevalence of NRT use for harm reduction Probability sample with
random digit dialling;
(1993–1999)
3,024 current and ex-smokers. 48.5% male, with a 45% between the
age of 31 and 45. 58% had an income above $30,000
Prevalence of NRT use for harm reduction
Note: NRT = Nicotine Replacement Therapy; SD = Standard Deviation; FTND = Fagerstrom Test for Nicotine Dependence; CO = carbon monoxide Dependence
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Figure 1
Flow of information through the different phases of the systematic review
ever used NRT to tide themselves over during periods
of abstinence, for example, on planes, in restaurants and
on trains (Etter et al., 2003; Levy et al., 2007), or if they
had ever used NRT during periods of time when they
were unable to smoke/where smoking was not permitted
(Hughes et al., 2004ab; Hughes et al., 2005; ITC; STS). One
study used open-ended questions to assess the reasons for
NRT use, with responses categorised into ‘to try to quit’,
‘to tide one over in situations where I cannot smoke’, ‘to
replace some cigarettes so I smoke less’ and ‘just curious’
(Al-Delaimy et al., 2005). Only six studies checked that
smokers were reducing without aiming to quit smoking
(Bansal et al., 2004; Hughes et al., 2005; ITC; Levy et al.,
2007; STS; Thorndike et al., 2002).
Quality assessment and risk of bias
Table 2 summarises the results of the quality assessment.
Most of the studies were of poor to moderate quality, with
only three studies classed as good quality (Hughes et al.,
2004; Levy et al., 2007; STS). Those studies categorised
as being of low quality could bias results in a number
of ways: (1) many asked smokers to retrospectively recall
their NRT use for harm reduction purposes, the reliabil-
ity of which is dependent on smokers’ ability to remember
their previous usage ofNRT; (2) the recruitment of unrep-
resentative samples in a number of the studies undermines
their generalisation to thepopulationof smokers; (3) some
of the studies were underpowered and so would not have
been able to detect differences even if these existed; and
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Table 2
Summary of the quality assessment of included studies
Study
Representative
sample
Adequate
sampled
size
Assessment
of current
NRT use Prospective/Cross-sectional
Quality measure for
the assessment of
prevalencea
Quality measure for
the assessment of
‘effectiveness’a
Al-Delaimy et al 2005 Yes Yes No – 2 –
Bansal et al 2004 Yes Yes No – 2 –
STS Yes2 Yes2 Yes Cross-sectional/ Prospective 3 3
Etter et al 2003 No Yes No Cross-sectional 1 1
ITC Yes Yes No Cross-sectional/ 2 1
Hughes et al 2004 No Yes Yes Prospective 2 3
Hughes et al 2004a No No Yes Cross-sectional 1 1
Hughes et al 2004b No No No – 1 –
Hughes et al 2005 No No No – 1 –
Levy et al 2007 Yes Yes No Cross-sectional/Prospective 2 3
Shiffman et al, 2003 No Yes Yes – 2 –
Thorndike et al, 2002 Yes Yes No – 2 –
NRT = Nicotine Replacement Therapy; – = Not applicable
1Beard et al [STS refers to the combination of data from Beard et al (2011a), Beard, Filder and West (2011b) and Beard et al (in press)
2Beard, Fidler and West (2011b) did not recruit a representative sample or a sample of an adequate size
a Quality measure 1 = Poor quality, 2 = Moderate quality, 3 = Good quality
(4) many were cross-sectional in nature, resulting in the
inability to determine the true direction of the relation-
ships reported (Etter et al., 2003; Hughes et al., 2004ab;
Hughes et al., 2005; ITC). Other sources of bias include
a dependence on ‘Westernised samples’ and diversity in
the periods of data collection (1987–2010). Since the early
1990s substantial changes have occurred in the licensing
of NRT and in the acceptability of smoking.
Prevalence of NRT use
Five studies assessed the past ever use of NRT for harm
reduction among smokers generally (Al-Delaimy et al.,
2005; Bansal et al., 2004; Etter et al., 2003; Levy et al., 2007;
Thorndike et al., 2002) (see Table 3); of these, four consid-
ered the use of NRT separately for smoking reduction and
three for periods of temporary abstinence. These studies
respectively provided data on 11,655 and 10,609 smok-
ers. Nine per cent (Confidence Interval (CI) 8.3–9.3) of
smokers were found to have ever usedNRT to reduce their
cigarette consumption and 5% (CI 4.4–5.2) for periods of
time when they were unable to smoke. One further study
assessed the use in the past year (ITC), noting that less than
6% of smokers had used NRT for temporary abstinence
and/or smoking reduction. Only one study assessed the
current use of NRT for harm reduction purposes, report-
ing a prevalence of 14% for smoking reduction and 14%
for temporary abstinence (STS). Two studies assessed gum
users’ reasons for initially purchasing NRT (Hughes et al.,
2004ab). These studies provided data on 366 smokers. Two
per cent of smokers (CI 0.9–3.9) reported that they had
initially purchased nicotine gum to tide them over during
periods of temporary abstinence, while 5% (CI 3.1–7.6)
had purchased nicotine gum initially for smoking reduc-
tion. Two further studies (Hughes et al., 2004a, Shiffman
et al., 2003) assessed the current use of nicotine gum for
harm reduction; only one of these (Shiffman et al., 2003)
assessed the use separately for smoking reduction and
temporary abstinence, reporting prevalence’s of 3% and
1% respectively. Finally, one study (Hughes et al., 2005)
assessed the initial reasons for using the nicotine inhala-
tor, reporting that 2% of smokers had purchased it for
temporary abstinence and 8% for smoking reduction.
The patch and gum were the most commonly used
form of NRT for harm reduction purposes (Bansal et al.,
2004; ITC; STS). Prevalence did not differ between coun-
tries, over time, or as a function of the extent to which
smoking restrictions were imposed (ITC; STS), but did
vary as a function of smokers’ characteristics. The use
of NRT for harm reduction was more common among
married smokers with a high nicotine dependency (Al-
Delaimy et al., 2005; Etter et al., 2003; Levy et al., 2007;
STS). Theuse ofNRT for smoking reductionwas also asso-
ciated with age, while the use of NRT for temporary absti-
nence with the ethnic category ‘White’ (Levy et al., 2007;
STS). Those using NRT for these purposes also tended
to have higher educational attainments and were more
reliant on cigarettes than those using NRT for smoking
cessation (Hughes et al., 2004a; ITC). The use of NRT for
harm reduction purposes was not associated with smok-
ers’ income, while findings for gender were inconsistent
(ITC; Levy et al., 2007; STS).
Reductions in cigarette consumption
In the cross-sectional analyses, the use of NRT for harm
reduction purposes was associated with higher cigarette
consumption (of around one to two cigarettes per day)
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Table 3
Prevalence of the use of Nicotine Replacement Therapy for smoking reduction and/or temporary abstinence
Category Study Participants
Use of NRT
for TA%
Use of NRT
for SR%
Use of NRT for
TA and SR%
All smokers – past ever use of
NRT
Al-Delaimy et al 2005 5,498 smokers from the US 3 1 –
Bansal et al 2004 1,046 smokers from the US – 13 –
Etter et al 2003 2,027 smokers from Switzerland 14 23 –
Levy et al 2007d 3,084 smokers from the US 2 11 4
Thorndike et al 2002 3,024 smokers from the US – – 14 d
All smokers – current use of NRT
STS 11,414 smokers from the UK 14 14 8
All smokers – use of NRT in the
past year
ITC 6,532 smokers from the UK, Canada,
US and Australia.
Overall 2
Canada 2
US 2 UK 2
Australia 1
Overall 1
Canada 2
US 1 UK 2
Australia 1
–
Nicotine gum users – current use
of NRT
Hughes et al 2004a 266 smokers from the US – – 8 c
Shiffman et al 2003 2,655 smokers from the US 1 3 –
Nicotine gum users – initial
purchase of NRT
Hughes et al 2004a 266 smokers from the US 1 6 –
Hughes et al 2004b 100 smokers from the US 4 2 –
Inhalator users – initial purchase
of NRT
Hughes et al 2005 535 smokers from the US 2 8 –
Note: NRT = Nicotine Replacement Therapy, TA = temporary abstinence, SR = smoking reduction – = Not applicable; c Prevalence of those using NRT for smoking reduction and/or
temporary abstinence; d Analysis restricted to patch and gum users only
relative to other smokers (Etter et al., 2003; Levy et al.,
2007), those attempting reductionwithoutNRT(STS) and
those using NRT for smoking cessation (ITC). Only two
of these studies adjusted for socio-demographic variables
and nicotine dependence (ITC; STS). In the prospective
analyses, Levy et al. (2007) found no association at two
years follow-up between the past use of NRT for smok-
ing reduction and/or temporary abstinence and a reduc-
tion of 50% or more in cigarette consumption. Hughes
et al. (2004) found greater reductions among reducers
who had used NRT at any time point over the previous
year. Smokers who had used NRT at years two, three,
four and five, also had more reduction in those years than
non-NRT users at the same points in time. Beard et al.
(STS) found that smokers reported slightly lower cigarette
consumption (around 1–2 cigarettes per day) at times
when they were using NRT for smoking reduction and/or
temporary abstinence compared to when they reported
smoking reduction or temporary abstinence without us-
ing NRT, but that this slight change was not associated
with a change in nicotine intake (measured using salivary
cotinine). Hughes et al. (2004a) also noted a reduction in
cigarette consumption when smokers reported that they
were using NRT for smoking reduction.
Attempts to quit smoking and smoking cessation
In the cross-sectional analyses positive associations were
reported between the use of NRT for smoking reduction
and past attempts to quit smoking (Levy et al., 2007; STS).
Beard et al. (STS) reported that those usingNRT for smok-
ing reductionwere 3.6 timesmore likely to have attempted
to quit smoking in the previous year than those cutting
downwithoutNRT,while Levy et al. (2007) that thosewho
had usedNRT to cut down in the past were 1.8 timesmore
likely to report a recent quit attempt than other smokers
generally. Findings were less consistent regarding the asso-
ciation between the use of NRT for temporary abstinence
and quit attempts; while Levy et al. (2007) failed to report
an association, Beard et al. (STS) reported that smokers
using NRT for TAwere 3.9 times more likely to havemade
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a recent quit attempt than smokers not using NRT for TA.
However, those using NRT for smoking reduction and/or
temporary abstinence were less likely to report a previous
quit attempt compared to those using NRT for smok-
ing cessation (ITC). People who used NRT to reduce or
for temporary abstinence were as likely to intend to quit
smoking as other smokers generally (Levy et al., 2007) but
were less likely to report an intention to quit than smokers
who had used NRT for smoking cessation (ITC).
In the prospective analyses, one study reported that
people who had used NRT to reduce or for temporary ab-
stinence were no more likely to attempt to quit smoking
or succeed in stopping than smokers not using NRT (Levy
et al., 2007), while another reported that NRT users were
more likely to attempt to quit smoking and stop (STS)
Beard et al. (STS) established that those using NRT for
smoking reduction were 1.6 times more likely to report
a quit attempt between baseline and follow-up, and 1.5
times more likely to report four-week point prevalence
cessation at follow-up, than those cutting down without
NRT. Those using NRT for temporary abstinence were
1.9 times more likely to report a quit attempt and twice
as likely to be abstinent at follow-up than those not us-
ing NRT for such purposes. Of interest, is that messages
informing smokers that NRT could be used to manage
smoke-free situations appeared to have no impact onmo-
tivation to quit, while a message that it could be used for
smoking reduction increased motivation to stop smoking
(Etter et al., 2003). Only two of these studies adjusted for
confounding variables (ITC; STS).
Discussion
This is the first review to synthesise evidence about the
prevalence of NRT use for harm reduction. The finding
that a minority of smokers have ever used NRT for such
purposes is unsurprisinggiven that studies suggest that less
than 20% of smokers who are attempting to quit smok-
ing use medicinal nicotine (Zhu et al., 2000). The cost of
concurrently purchasing NRT and cigarettes is likely to
partially account for the low prevalence of use (Bauer
et al., 2006; Johnson et al., 1992), as are the negative
beliefs many smokers hold towards NRT (Bansal et al.,
2004; Cummings et al., 2004; Hajek et al., 1999; John-
son et al., 1992; Miller et al., 2005). The pharmaceutical
industries have also historically directed their heavily in-
vested consumer advertising of NRT towards those smok-
ers who are already primed to stop smoking or to reduce
on their own (Cummings & Hyland, 2005). Moreover,
product labelling has been rather cautious and out-dated.
Although this has now largely been rectified in the UK, in
other countries NRT product labels imply to consumers
that the medication is only for cessation purposes and
dangerous if taken for prolonged periods of time (Shiff-
man et al., 2008). However, although there was little evi-
dence of within study changes in prevalence (ITC; STS),
those studies conductedmore recently had a higher preva-
lence of NRT use for harm reduction; pointing towards
the possibility that more smokers may start to use NRT
for non-cessation purposes in the coming years.
The use of NRT for smoking reduction and/or dur-
ing periods of temporary abstinence was more common
among older smokers and those with higher nicotine de-
pendency; giving some indication as to those who may be
the most receptive of a harm reduction approach. Since
smokers with a greater reliance on cigarettes are likely
to find it harder to cope with momentary abstinence, it
is perhaps of little surprise that they are more likely to
opt to use NRT. There is also evidence that older smok-
ers hold greater positive beliefs about medication gener-
ally (Horne & Weinman, 1999). As these findings largely
coincide with studies on the characteristics of those us-
ing NRT for smoking cessation (Botello-Harbaum et al.,
2010; Emmons et al., 2000; Kotz et al., 2009), they raise
the concern that tobacco harm reduction approaches may
not be reaching a sub-set of smokers who are unwilling
or unable to quit smoking. This certainly requires further
investigation; although Hammond et al. (STS) did estab-
lish differences among those using NRT for cessation and
non-cessation purposes.
In contrast to the findings from the clinical trials
(Asfar et al., 2011; Fagerstrom, 2005; Hughes, 2000;
Hughes & Carpenter, 2006; Moore et al., 2009; Stead
& Lancaster, 2007; Tonnesen, 2002; Wang et al., 2008;
Zellweger, 2001), the use of NRT for smoking reduc-
tion in population surveys does not appear to be asso-
ciated with sizable reductions in cigarette consumption.
Although no randomised controlled trial has considered
theuseofNRTfor temporary abstinence, the lackof reduc-
tions in cigarette consumption is also rather surprising.
One would assume that NRT would mitigate a tendency
to compensate prior to and following periods of momen-
tary abstinence, with a reduction in cigarette consumption
consequently occurring.
The findings regarding the association with smoking
cessation are less than consistent. In the cross-sectional
analyses the use of NRT for harm reduction purposes was
associated with increased odds of a previous attempt to
quit smoking relative to other smokers generally/those
not using NRT for harm reduction purposes (Levy et al.,
2007; STS). However, this could be for many reasons: it
may be that the use of NRT for smoking reduction in-
creases smokers’ motivation to quit; it may be that use
of NRT and attempts at cessation are both manifestations
of a general tendency to try and mitigate the harmful ef-
fects of smoking; it could also be that the use of NRT for
smoking reduction is an after effect of a failed quit at-
tempt. Prospective analyses partially resolve the issue of
causality inherent in the cross-sectional studies, with one
prospective study failing to find an association between
the use of NRT for harm reduction purposes and attempts
to stop smoking (Levy et al., 2007), while another found a
beneficial effect of NRT use on smoking cessation (STS).
This may have been because the prior study was plagued
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bymethodological issues: (1) a follow-up of two years and
no intermediate assessments; (2) themeasurement of past
ever NRT use as opposed to current use; and (3) a failure
to adjust for confounding variables.
Limitations
The studies included in this review were biased in a num-
ber of ways. Firstly, many assessed the past use of NRT;
a measure which is highly confounded by smokers’ abil-
ity to accurately remember situations in which they used
medicinal nicotine (Berg et al., 2010). Secondly the use
of advertisements in order to recruit samples is likely to
have resulted in selection bias. Consequently, any findings
are unlikely to generalise to the population of NRT users.
More weight should therefore be given to studies using
sampling methods such as random digit dialling or ran-
dom location sampling, which aim to attain a population-
based cohort. Thirdly, few studies adjusted for nicotine
dependency or any other potential confounding variables.
This limits the conclusions that can be drawn, especially
regarding cross-sectional data. It may be that those us-
ing NRT for smoking reduction are not found to smoke
fewer cigarettes than other smokers simply because they
were a prior more nicotine dependent. Fourthly, no study
assessed the extent of NRT use and length of use; two fac-
tors which may account for lack of reliable reductions in
cigarette intake. Fifthly, there is a need in future to include
biological measures of disease risk. The one study to do so
found stability in salivary cotinine prior to and following
NRT use, despite little reduction in cigarette intake (Beard
et al., 2011b). This points to the possibility that smokers
may compensate for the additional nicotine from NRT by
modifying how they smoke their cigarettes; a possibility
that needs to be considered further. Finally, all of the stud-
ies were conducted in the ‘Western World’; thus there is a
need to assess whether the findings reported here gener-
alise to other countries perhaps that do not possess such
extensive smoking or NRT product restrictions.
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